Neoadjuvant treatment for borderline resectable pancreatic adenocarcinoma is associated with higher R0 rate compared to upfront surgery.

Mario TerlizziEtienne BuscailOlayidé BoussariSarah AdgiéNicolas LeducEric TerrebonneDenis SmithJean-Frédéric BlancBruno LapuyadeChristophe LaurentLaurence ChicheGeneviève BelleannéeKarine Le MalicotRenaud TrouetteClaudia PouypoudatVéronique Vendrely

Published in: Acta oncologica (Stockholm, Sweden) (2021)

NAT permitted a high R0 rate with a 0- or 1-mm clearance margin and was associated with better RFS and OS for patients with BRPC.

Keyphrases

locally advanced
minimally invasive
rectal cancer
lymph node
coronary artery bypass
squamous cell carcinoma
acute coronary syndrome
liver metastases
atrial fibrillation